Loperamide 1980s, prior to the expiration of US patent on 30 January 1990, McNeil company started to develop Imodium Advanced containing loperamide and simethicone for treating both diarrhea and gas. In March 1997, the company patented such combination. The drug was approved in June 1997 by the FDA as Imodium Multi-Symptom Relief in the form of a chewable tablet. In November 1993, loperamide was launched as an orally disintegrating tablet based on Zydis technology. Imodium Instant Melts from Johnson & Johnson is currently the only loperamide available in the form of orally disintegrating tablets. In 2013, loperamide in the form of
Heterogeneous condition also define a "medical condition" as any illness, injury, or disease except for psychiatric illnesses. As it is more value-neutral than terms like "disease", the term "medical condition" is sometimes preferred by people with health issues that they do not consider deleterious. It is also preferred when etiology is not unique, because the word disease is normally associated to the cause of the clinical problems. On the other hand, by emphasizing the medical nature of the condition, this term is sometimes rejected, such as by proponents of the autism rights movement. The term is also used in specialized areas of